Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab
Summit Therapeutics has outlined November 14 as the FDA PDUFA date for its ivonescimab Biologics License Application (BLA) and plans for HARMONi-3 PFS in the second half of 2026.
Results for "ivonescimab"
5 stories found
Akeso Lung Cancer Drug Shows Promising Trial Results
New clinical trial results indicate that drugs from Akeso and Lilly are showing promise in treating lung cancer. Akeso's drug, ivonescimab, has announced better-than-expected clinical results for a type of lung cancer, potentially expanding its application, while Lilly's Retevmo reduced the risk of recurrence in a late-stage trial.
Summit Reports Positive Phase III Overall Survival Data for Ivonescimab
Summit (SMMT) reported positive Phase III overall survival data for its drug Ivonescimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC).
Summit Therapeutics Focuses on Ivonescimab Trial for Non-Small Cell Lung Cancer
Summit Therapeutics Inc. is concentrating its efforts on the clinical trial of Ivonescimab, a drug being developed for the treatment of non-small cell lung cancer.
Experimental Lung Cancer Drug Ivonescimab Shows Promise, Reduces Death Risk by 34%
A highly anticipated study revealed that the experimental lung-cancer drug ivonescimab reduced the risk of death by 34% compared with another drug, though investors' reaction was muted.